Research programme: Middle East respiratory syndrome coronavirus nanoparticle therapies - NanoViricides
Alternative Names: MERS-CoV therapeutic - NanoViricidesLatest Information Update: 26 Jul 2019
At a glance
- Originator NanoViricides
- Developer Lovelace Respiratory Research Institute; NanoViricides
- Class Antivirals; Polymers; Viral envelope proteins
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Middle East respiratory syndrome coronavirus
Most Recent Events
- 26 Jul 2019 Discontinued for Middle East respiratory syndrome coronavirus in USA (Parenteral)